Key points are not available for this paper at this time.
Background: Globally, the probiotics are often defined as live microorganisms that provide various health benefits. One such probiotic strain is Bacillus Coagulans, which has emerged as a promising strain for its role in the enhancing protein absorption that is a critical component of overall nutritional health. Methodology: The current study is a randomized control clinical trial to test the efficacy of probiotic ProBC Plus (Bacillus Coagulans LMG S-31876) product for 8 weeks. This double-blind, randomized control study, the two parallel groups having 14 individuals in test group and 16 individuals in the placebo group were monitored closely. Furthermore, major GI symptoms as well as protein absorption over 8 weeks was observed. Results: ProBC Plus (Bacillus Coagulans LMG S-31876) did not aggravate or have any adverse effects on GI disorders/symptoms during the course of consumptions and outcome was statistically significant. Furthermore, the study shows a average urine urea nitrogen among the test group was statistically significant when compare with placebo group and within the normal reference range. Thus, ProBC Plus (Bacillus Coagulans LMG S-31876) has the potential to optimize protein utilization efficiently. Conclusion: Research reveals that ProBC Plus (Bacillus Coagulans LMG S-31876) not only enhances protein absorption but also promotes better overall digestive health.
Bhattacharya et al. (Mon,) studied this question.